vadastuximab talirine + cytarabine

Vadastuximab talirine + cytarabine is an experimental **combination regimen** for acute myeloid leukemia (AML). **Vadastuximab talirine** is an antibody-drug conjugate (ADC) consisting of a humanized monoclonal antibody targeting **CD33** (a myeloid cell surface antigen highly expressed in AML), conjugated via a protease-cleavable dipeptide linker to pyrrolobenzodiazepine (PBD) dimers, a potent DNA cross-linking cytotoxin[1][2][3][4][5][6]. Upon binding CD33, the ADC is internalized, releasing the cytotoxic payload to induce DNA damage and cell death in leukemia cells[1][2][4][5][6]. **Cytarabine** is a cytotoxic chemotherapy agent (antimetabolite) that inhibits DNA synthesis by incorporation into DNA and chain termination. Combination therapy of vadastuximab talirine with cytarabine (most commonly as part of the "7+3" induction regimen) has been evaluated in clinical trials for newly diagnosed AML: vadastuximab talirine is administered concomitantly with cytarabine (and sometimes daunorubicin), aiming to enhance anti-leukemic efficacy by targeting multiple pathways of leukemic cell kill[3].